ebetaxel 150mg 25ml infusion concentrate for - search results

docetaxel 20 mg/ml concentrate for solution for infusion

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - docetaxel - concentrate for solution for infusion - docetaxel 20 mg - antineoplastic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

gn-docetaxel docetaxel 80mg/2ml concentrated solution for injection vial with diluent vial

alphapharm pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: water for injections; ethanol absolute; citric acid; polysorbate 80 - 1. breast cancer a) metastatic breast cancer,gn-docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. gn-docetaxel injection in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. gn-docetaxel injection in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease.,b). adjuvant treatment of breast cancer,gn-docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by gn-docetaxel injection in combination with trastuzumab (ac- th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. gn-docetaxel injection in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. gn-docetaxel injection in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of greater than or equal to 1cm and < 7cm.,2. non small cell lung cancer,gn-docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy.,3.ovarian cancer,gn-docetaxel injection is indicated for the treatment of metastatic carcinoma of the ovary after failure of first- line or subsequent chemotherapy.,4.prostate cancer,gn-docetaxel injection is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer.,5. head and neck cancer,gn-docetaxel injection, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Ireland - English - HPRA (Health Products Regulatory Authority)

docetaxel 80 10 milligram concentrate for soln for inf

seacross pharmaceuticals - docetaxel anhydrous - concentrate for soln for inf - 80 10 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

docetaxel ebewe 10 mg/ml concentrate for soln for inf

ebewe pharma ges.m.b.h nfg. kg - docetaxel - concentrate for soln for inf - 10 mg/ml

European Union - English - EMA (European Medicines Agency)

docetaxel accord

accord healthcare s.l.u. - docetaxel - head and neck neoplasms, carcinoma, non-small-cell lung, adenocarcinoma, prostatic neoplasms, breast neoplasms - antineoplastic agents, - breast cancerdocetaxel accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.for patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.docetaxel accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.docetaxel accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent.docetaxel accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer w